DMK Pharmaceuticals (OTCPK:DMKP.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

DMKP.Q Stoklara Genel Bakış

Klinik aşamada bir nöro-biyoteknoloji şirketi olan DMK Pharmaceuticals Corporation, alerji, aşırı dozda opioid, solunum ve enflamatuar hastalıkların terapötik alanlarında ürünler geliştirmekte ve ticarileştirmektedir.

Şirket hakkında

DMKP.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Revenue grew by 150.3% over the past year

Risk Analizi

Negative shareholders equity

Does not have a meaningful market cap ($10)

Highly volatile share price over the past 3 months compared to the US market

Latest financial reports are more than 6 months old

+ 2 daha fazla risk

DMK Pharmaceuticals Corporation Rakipler

NVN Liquidation

OTCPK:NOVN.Q

US$28.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Clever Leaves Holdings

OTCPK:CLVR

US$175.0

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti DMK Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.000001
52 Haftanın En Yüksek Seviyesi	US$1.04
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	1.22
11 Aylık Değişim	-99.90%
3 Aylık Değişim	-99.00%
1 Yıllık Değişim	-100.00%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Jul 29

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Jul 21

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Apr 13

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Jan 20

Adamis Pharmaceuticals: It's Now Or Never

Dec 02

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Sep 03

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Jun 13

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Jun 07

Adamis pharmaceuticals gets deficiency letter from NASDAQ

May 28

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Jan 29

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Nov 16

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Nov 09

Hissedar Getirileri

	DMKP.Q	US Pharmaceuticals	US Pazar
7D	0%	-3.7%	-1.6%
1Y	-100.0%	17.2%	30.8%

Getiri vs. Endüstri: DMKP.Q underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.

Getiri vs Piyasa: DMKP.Q underperformed the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is DMKP.Q's price volatile compared to industry and market?
DMKP.Q volatility
DMKP.Q Average Weekly Movement	449,369.7%
Pharmaceuticals Industry Average Movement	9.3%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: DMKP.Q's share price has been volatile over the past 3 months compared to the US market.

Zaman İçindeki Volatilite: DMKP.Q's weekly volatility has increased from 196460% to 449370% over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	12	Eddie Glover	www.dmkpharmaceuticals.com

Klinik aşamada bir nöro-biyoteknoloji şirketi olan DMK Pharmaceuticals Corporation, alerji, aşırı doz opioid, solunum ve enflamatuar hastalıkların terapötik alanlarında ürünler geliştirmekte ve ticarileştirmektedir. Şirketin önde gelen klinik aşama ürün adayı, opioid kullanım bozukluğunun tedavisi için endike olan DPI-125'tir. Ürünleri arasında sokan ve ısıran böceklere, alerjen immünoterapisine, gıdalara, ilaçlara, tanısal test maddelerine ve diğer alerjenlere karşı alerjik reaksiyonların yanı sıra idiyopatik veya egzersize bağlı anafilaksinin acil tedavisi için SYMJEPI epinefrin enjeksiyonu ve opioid aşırı dozunun tedavisi için ZIMHI nalokson enjeksiyonu bulunmaktadır.

DMK Pharmaceuticals Corporation Temel Bilgiler Özeti

DMK Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DMKP.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$10.00
Kazançlar(TTM)	-US$21.33m
Gelir(TTM)	US$3.62m

0.0x

P/S Oranı

0.0x

F/K Oranı

DMKP.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DMKP.Q gelir tablosu (TTM)
Gelir	US$3.62m
Gelir Maliyeti	US$4.97m
Brüt Kâr	-US$1.35m
Diğer Giderler	US$19.98m
Kazançlar	-US$21.33m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.11
Brüt Marj	-37.30%
Net Kâr Marjı	-589.28%
Borç/Özkaynak Oranı	0%

DMKP.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

DMKP.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

DMK Pharmaceuticals Corporation Rakipler

OTCPK:NOVN.Q

US$28.0

OTCPK:PLXP.Q

US$30.0

OTCPK:RVLP.Q

US$111.0

OTCPK:CLVR

US$175.0

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation

First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation

Nasdaq to Delist Common Stock of DMK Pharmaceuticals

DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index

Recent updates

Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation

First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation

Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation

Nasdaq to Delist Common Stock of DMK Pharmaceuticals

DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index

DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024

DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI

Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock Market

DMK Pharmaceuticals Corporation Announces CFO Changes

DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirements

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023

Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.

Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes

Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023

Adamis Pharmaceuticals Corporation to Report Q3, 2022 Results on Nov 14, 2022

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Adamis Pharmaceutics Corporation Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation to Report Q2, 2022 Results on Aug 10, 2022

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of Covid-19

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Adamis Pharmaceuticals Corporation announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Adamis Pharmaceuticals Corporation to Report Q1, 2022 Results on May 16, 2022

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Richard C. Williams Notifies Adamis Pharmaceuticals Corporation That Effective April 15, 2022, He Will Be Retiring

Adamis Pharmaceuticals Corporation’S Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

Adamis Pharmaceuticals Corporation Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Adamis Pharmaceuticals Corporation Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Adamis Pharmaceuticals Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 Mg Intramuscular Dose of Naloxone in Zimhi™

Adamis Pharmaceuticals: It's Now Or Never

Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Adamis Pharmaceuticals Receives A Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

An unknown buyer completed the acquisition of U.S. Compounding, Inc. from Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) for $15 million.

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

Adamis Provides Update on ZIMHI™

Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ

Adamis pharmaceuticals gets deficiency letter from NASDAQ

Adamis Pharmaceuticals Corporation announced delayed amended 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing